Axsome Therapeutics (AXSM) Invested Capital (2016 - 2026)

Axsome Therapeutics has reported Invested Capital for 11 years, with the latest figure at $11.2 million in Q1 2026.

• Quarterly Invested Capital fell 93.81% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $371.2 million (down 48.45% YoY) and the FY2025 annual result came in at $120.0 million, down 33.33% from the prior year.
• Invested Capital declined to $11.2 million in Q1 2026 per AXSM's latest filing, from $120.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $180.0 million in Q2 2023 and troughed at $11.2 million in Q1 2026.
• A 5-year average of $135.1 million and a median of $150.0 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2026: Invested Capital jumped 200.0% in 2023, then tumbled 93.81% in 2026.
• Over 5 years, Invested Capital stood at $95.0 million in 2022, then soared by 89.47% to $180.0 million in 2023, then changed by 0.0% to $180.0 million in 2024, then plunged by 33.33% to $120.0 million in 2025, then sank by 90.71% to $11.2 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $11.2 million, $120.0 million, and $120.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.